home / stock / aps:cc / aps:cc quote
Last: | $0.93 |
---|---|
Change Percent: | -5.1% |
Open: | $0.98 |
Close: | $0.98 |
High: | $0.98 |
Low: | $0.91 |
Volume: | 17,948 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.93 | $0.98 | $0.98 | $0.98 | $0.91 | 17,948 | 08-02-2022 |
$1.51 | $1.52 | $1.51 | $1.53 | $1.45 | 51,523 | 05-06-2022 |
$1.57 | $1.5 | $1.57 | $1.57 | $1.46 | 64,334 | 05-05-2022 |
$1.52 | $1.55 | $1.52 | $1.55 | $1.44 | 38,848 | 05-04-2022 |
$1.54 | $1.51 | $1.54 | $1.56 | $1.51 | 16,111 | 05-03-2022 |
$1.52 | $1.53 | $1.52 | $1.53 | $1.46 | 12,175 | 05-02-2022 |
$1.5 | $1.52 | $1.5 | $1.52 | $1.46 | 22,510 | 04-29-2022 |
$1.47 | $1.49 | $1.47 | $1.5 | $1.45 | 13,231 | 04-28-2022 |
$1.44 | $1.47 | $1.44 | $1.52 | $1.44 | 25,867 | 04-27-2022 |
$1.46 | $1.54 | $1.46 | $1.54 | $1.44 | 34,196 | 04-26-2022 |
$1.46 | $1.46 | $1.46 | $1.49 | $1.42 | 68,212 | 04-25-2022 |
$1.46 | $1.47 | $1.46 | $1.47 | $1.39 | 32,972 | 04-22-2022 |
$1.44 | $1.53 | $1.44 | $1.53 | $1.42 | 63,944 | 04-21-2022 |
$1.46 | $1.49 | $1.46 | $1.51 | $1.46 | 100,865 | 04-20-2022 |
$1.52 | $1.52 | $1.52 | $1.55 | $1.48 | 71,145 | 04-19-2022 |
$1.51 | $1.59 | $1.51 | $1.59 | $1.46 | 55,261 | 04-18-2022 |
$1.58 | $1.58 | $1.58 | $1.6 | $1.56 | 21,589 | 04-15-2022 |
$1.58 | $1.58 | $1.58 | $1.6 | $1.56 | 21,527 | 04-14-2022 |
$1.6 | $1.57 | $1.6 | $1.63 | $1.57 | 26,577 | 04-13-2022 |
$1.61 | $1.66 | $1.61 | $1.7 | $1.56 | 62,026 | 04-12-2022 |
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APS:CC Stock Symbol:
TSXC Market:
Aptose Biosciences Inc. Website:
A look at the top 10 most actives in Canada Calibre Mining Corp. (CXB) fell 2.9% to $1.835 on volume of 79,684,444 shares Canadian Natural Resources Limited (CNQ) rose 1.6% to $48 on volume of 6,456,525 shares Alaris Equity Partners Income Trust 5.50% convertible unsecured subordinated de...
SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies,...
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in...